Biotest Aktiengesellschaft
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for… Read more
Biotest Aktiengesellschaft (BIESF) - Total Liabilities
Latest total liabilities as of March 2025: $906.90 Million USD
Based on the latest financial reports, Biotest Aktiengesellschaft (BIESF) has total liabilities worth $906.90 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biotest Aktiengesellschaft - Total Liabilities Trend (2002–2024)
This chart illustrates how Biotest Aktiengesellschaft's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biotest Aktiengesellschaft Competitors by Total Liabilities
The table below lists competitors of Biotest Aktiengesellschaft ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Century Iron And Steel Industrial Co Ltd
TW:9958
|
Taiwan | NT$20.22 Billion |
|
Shanghai SK Automation Technology Co. Ltd. A
SHG:688155
|
China | CN¥3.02 Billion |
|
Edifier Technology Co Ltd
SHE:002351
|
China | CN¥588.95 Million |
|
Collins Foods Limited
PINK:CLLFF
|
USA | $689.80 Million |
|
Cyfrowy Polsat S.A
OTCGREY:CYFWF
|
USA | $20.27 Billion |
|
Weis Markets Inc
NYSE:WMK
|
USA | $674.38 Million |
|
Jiangsu Provincial Agricultural Reclamation and Development Co Ltd
SHG:601952
|
China | CN¥7.46 Billion |
Liability Composition Analysis (2002–2024)
This chart breaks down Biotest Aktiengesellschaft's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotest Aktiengesellschaft's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotest Aktiengesellschaft (2002–2024)
The table below shows the annual total liabilities of Biotest Aktiengesellschaft from 2002 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $903.30 Million | -0.95% |
| 2023-12-31 | $912.00 Million | +9.63% |
| 2022-12-31 | $831.90 Million | +14.94% |
| 2021-12-31 | $723.80 Million | +4.94% |
| 2020-12-31 | $689.70 Million | +9.22% |
| 2019-12-31 | $631.50 Million | +15.43% |
| 2018-12-31 | $547.10 Million | -13.26% |
| 2017-12-31 | $630.70 Million | +10.24% |
| 2016-12-31 | $572.10 Million | +3.94% |
| 2015-12-31 | $550.40 Million | -0.36% |
| 2014-12-31 | $552.40 Million | +29.73% |
| 2013-12-31 | $425.80 Million | +36.08% |
| 2012-12-31 | $312.91 Million | -6.90% |
| 2011-12-31 | $336.09 Million | +3.50% |
| 2010-12-31 | $324.73 Million | -10.69% |
| 2009-12-31 | $363.59 Million | +7.36% |
| 2008-12-31 | $338.67 Million | +8.92% |
| 2007-12-31 | $310.94 Million | +24.22% |
| 2004-12-31 | $250.31 Million | +1.47% |
| 2003-12-31 | $246.69 Million | -5.55% |
| 2002-12-31 | $261.20 Million | -- |